Filing Flows

Filing Flows › Companies › Pyxis Oncology › Cash flow

Pyxis Oncology cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$16.3M in Q3 2026 · −$70.9M over twelve months

Operating cash flow−$16.3M
Free cash flow−$16.3M

Analysis

In Q3 2026, Pyxis Oncology generated −$16.3M of operating cash flow. That is $3.0M less than in Q3 2025 (−$13.3M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$70.9M; the largest uses were operating cash flow ($70.9M), taxes on employees’ shares ($184K); besides operations, cash came from other financing ($48.5M), other investing ($16.6M); the cash balance fell by $5.1M.

Operating cash flow was −$16.3M against net income of −$20.0M. The largest differences: payables +$4.9M, accrued liabilities −$2.5M, stock-based pay +$1.3M.

Free cash flow

Pyxis Oncology: free cash flow by quarterPyxis Oncology: free cash flow by quarter−$19.3MQ4 2024−$22.5MQ1 2025−$17.3MQ2 2025−$13.3MQ3 2025−$10.4MQ4 2025−$26.0MQ1 2026−$18.2MQ2 2026−$16.3MQ3 2026
Operating cash flow less capital spending.
Pyxis Oncology: operating cash flow against capital spendingPyxis Oncology: operating cash flow against capital spendingOperating cash flowCapital spending−$19.3M$0Q4 2024−$22.5M$0Q1 2025−$17.3M$0Q2 2025−$13.3M$0Q3 2025−$10.4M$0Q4 2025−$26.0M$0Q1 2026−$18.2M$0Q2 2026−$16.3M$0Q3 2026
Latest (Q3 2026): Operating cash flow −$16.3M, Capital spending $0.

Capital allocation, year by year

Pyxis Oncology: where the cash came from (up) and went (down), by fiscal yearPyxis Oncology: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow −$35.3MFY2021: Shares issued $304MFY2021: Capital spending −$540K$304MFY2021FY2022: Operating cash flow −$89.3MFY2022: Shares issued $183KFY2022: Capital spending −$6.4M$183KFY2022FY2023: Operating cash flow −$70.7MFY2023: Shares issued $120KFY2023: Capital spending −$6.7M$120KFY2023FY2024: Operating cash flow −$57.7MFY2024: Shares issued $296KFY2024: Capital spending −$237K$296KFY2024FY2025: Operating cash flow −$63.5MFY2025: Shares issued $632KFY2025: Capital spending −$9K$632KFY2025
Over these 5 years operating cash flow totalled −$317M; the largest uses were operating cash flow ($317M) and capital spending ($13.9M). Cash-flow statements as filed.

Where the cash came from and went

Pyxis Oncology: sources (+) and uses (−) of cash, Q3 2026Pyxis Oncology: sources (+) and uses (−) of cash, Q3 2026Other financing$38.3MOther investing−$37.3MOperating cash flow−$16.3MCash drawn (+) / kept (−)$15.0MShares issued$275KTaxes on employees’ shares−$35K
Pyxis Oncology: sources (+) and uses (−) of cash, TTM to Q3 2026Pyxis Oncology: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow−$70.9MOther financing$48.5MOther investing$16.6MCash drawn (+) / kept (−)$5.1MShares issued$954KTaxes on employees’ shares−$184K

From profit to cash

Pyxis Oncology: net income to operating cash flow, Q3 2026Pyxis Oncology: net income to operating cash flow, Q3 2026Net income−$20.0MDepreciation & amortization$299KStock-based pay$1.3MPayables$4.9MAccrued liabilities−$2.5MPrepaid and other assets$183KOperating cash flow−$16.3M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$16.3M$275K$15.0M−$16.3M
Q2 2026−$18.2M—−$13.1M−$18.2M
Q1 2026−$26.0M—$9.7M−$26.0M
Q4 2025−$10.4M$632K−$6.5M−$10.4M
Q3 2025−$13.3M—$1.8M−$13.3M
Q2 2025−$17.3M—$2.0M−$17.3M
Q1 2025−$22.5M—$6.7M−$22.5M
Q4 2024−$19.3M$3K−$7.4M−$19.3M

Pyxis Oncology: income statement and cash flow

Pyxis Oncology, Q4 2025: revenue $11.0M, operating margin -165.7%. The chart follows the revenue to costs, profit and cash.

Pyxis Oncology: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.